β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials
Pooled resultResult — go to the resultHazard ratio 0.75 95% CI 0.58–0.97Authors' conclusion
In patients with acute myocardial infarction with mildly reduced LVEF without history or clinical signs of heart failure, β-blocker therapy was associated with a reduction in the composite of all-cause death, new myocardial infarction, or heart failure.
Study context
- Population
- Patients with recent MI and mildly reduced left ventricular ejection fraction (LVEF) (40–49%), no history or signs of HF
- Participants
- 1,885 patients4 RCTs
- Comparison
- β blockers vs no β blockers
- β blockersn = 991
- No β blockersn = 894reference
- Outcome
- Composite of:
- All-cause death
- New MI
- HF
Methodological detailsone-stage, fixed-effects, independently adjudicated endpoints
- One-stage
- Fixed-effects
- Independently adjudicated endpoints
Pooled result
As reported in the abstract
Hazard ratio
0.75
95% CI 0.58–0.97
P = 0.031
Events by group
β blockers
32.6 events per 1000 patient-years
106 of 991
No β blockers
43.0 per 1000 patient-years
129 of 894
β blockersvs No β blockers
HR 0.75 (95% CI 0.58–0.97); P = 0.031
Original publication
β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. Lancet. Published 30 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →